When your drug's clinical data is strong but your payer evidence is not landing, that is where we work
HEOR, Real-World Evidence, and HTA strategy for pharmaceutical and biotech teams navigating global market access.
Ready to begin
Working on a submission, a model, or a strategy?
The Baseline
If this is your
current reality
Your drug has strong Phase 3 data, but the economic model for your HTA (eg; NICE or G-BA submission) is not built – or was not built for that specific payer.
Your team does not have in-house HEOR depth for this submission cycle, and you need senior-level involvement, not a junior associate from a large CRO.
You are entering an emerging market – SE Asia, LatAm, Eastern Europe, – and need someone who understands those HTA bodies from the inside, not from a template.
Does this sound like your challenge?
Let’s discuss your submission strategy and how we can provide the senior-level HEOR depth you need.
Tell us about your projectCore Capabilities
Beyond Data,
Real Market Access
Six areas of deep specialisation. Every engagement is led directly by Dr. Goyal's team-never delegated to junior associates.
See our full expertiseHealth Technology Assessment
Submission-ready evidence packages for NICE, G-BA, PBAC, CADTH, ACE, and HITAP.
Pharmacoeconomic Modelling
Cost effectiveness, budget impact analysis burden of disease models using Markov, partitioned survival models, and decision-tree analyses built for specific payer requirements
Systematic Literature Review & Evidence Synthesis
GRADE-compliant SLRs, Bayesian network meta-analyses, and indirect treatment comparisons.
Real-World Evidence
Retrospective cohort studies, database analyses, and PRO study designs using real-world data sources.
Medical Communications
Value dossiers, global value frameworks, payer slide decks, and HTA submission narratives.
Global Market Access Strategy
Entry strategy, pricing and reimbursement planning, and stakeholder engagement across APAC and global markets.
How We Solve It
Confidential Outcomes
Three examples of complex problems solved. Client names are confidential. Methodology and outcomes are explicitly not.
Survival Extrapolation
A biotech client had 18-month overall survival data for a rare solid tumour - too immature for standard parametric extrapolation. We developed a Bayesian survival model anchored to external registry data, with a full structural uncertainty analysis. The submission was accepted for appraisal.
Cost-Utility Model
A mid-size pharma team needed a cost-utility model for a cardiovascular intervention targeting the Australian PBS listing. The comparator landscape was crowded with indirect evidence. We conducted a network meta-analysis, built a Markov model with a 10-year horizon, and delivered the full economic section of the PBAC major submission.
Value Dossier
A global biotech preparing for multi-country HTA submissions across EU5 and APAC needed a single global value dossier with country adaptation frameworks. We built the core dossier, adapted it for NICE, G-BA, and Singapore MOH, and provided the clinical and economic narrative for each market.
Dr. Richa Goyal
About Dual Sphere
Thefirmisbuiltonasingleoperatingprinciple:thepersonwiththemostexpertiseshouldbethemostinvolvedineveryproject-nottheleast.
Dual Sphere Consulting was founded by Dr Richa Goyal in 2025 to make senior-level HEOR expertise accessible without the overhead of a large CRO. Operating from Singapore, UK and India, with active engagements across APAC, ME, India, UK, Europe, and North America, the firm brings together a team of consultants, health economists, and medical writers with backgrounds across IQVIA, Parexel, TCS, and leading academic institutions.
Meet the teamThe Strategic Alliance
Empowering HEOR and RWE
through an integrated ecosystem
Dual Sphere Consulting operates within a deeply integrated global alliance. Engagements are backed by a proprietary network of joint-venture research institutes, methodology networks, and academic platforms.
Working on a submission, a
model, or a strategy?
Let's talk
We take on a focused number of engagements at any time to ensure senior-level attention on every project.
Start a conversation